This video provides an overview of Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare, acquired chronic hemolytic anemia caused by a mutation in the PIGA gene. The mutation affects myeloid stem cells, leading to a deficiency in GPI-anchored proteins like CD55 and CD59, which normally protect blood cells from complement-mediated destruction. The video explains the alternative complement pathway, the role of CD55 and CD59 in preventing self-attack, and the clinical manifestations, complications, and diagnosis of PNH. Finally, it discusses treatment options, including iron and folate supplementation, RBC transfusions, monoclonal antibody therapy (eculizumab), and stem cell transplantation.
Understanding Paroxysmal Nocturnal Hemoglobinuria (PNH): From Genetics to Treatment
0:00 Introduction to PNH: PNH is defined as an episodic (paroxysmal), nocturnal (at night) excretion of hemoglobin in the urine (hemoglobinuria).
0:15 Genetic Basis of PNH: PNH is an acquired hemolytic anemia due to a mutation in the PIGA gene found on the short arm of the X chromosome. This mutation occurs after birth in myeloid stem cells.
0:33 Role of GPI Anchor: The PIGA gene encodes an enzyme that synthesizes GPI, a protein which anchors complement regulatory proteins (CD55 and CD59) to the cell membrane.
0:41 Complement System Overview: The complement system is a part of the immune system that helps antibodies clear pathogens from the body. The alternative pathway is triggered by bacterial endotoxins.
0:47 Protection Against Self-Attack: CD55 and CD59 are complement regulatory proteins. CD55 prevents the formation of C3 convertase, while CD59 blocks the binding of C9, preventing the formation of the membrane attack complex (MAC).
0:59 Pathophysiology in PNH: In PNH, the PIGA gene mutation prevents the production of GPI, leading to a deficiency of CD55 and CD59 on the surface of red blood cells, neutrophils, and platelets. This makes these cells susceptible to complement-mediated destruction, primarily through intravascular hemolysis.
06:28 Clinical Presentation: The video highlights that because urine is more concentrated at night, PNH patients often experience the darkest urine first thing in the morning due to hemoglobinuria.
07:05 Complications of PNH: Complications include iron deficiency anemia (due to hemoglobin loss in urine), acute myeloid leukemia (AML), and thrombosis (especially venous). Venous thrombosis can lead to Budd-Chiari syndrome (hepatic vein thrombosis), portal vein thrombosis, or cerebral venous thrombosis. Infection is another significant cause of death.
07:54 Clinical Triad: The classic clinical triad of PNH includes hemolytic anemia, pancytopenia, and venous thrombosis.
08:02 Coexistence with Aplastic Anemia: PNH can coexist with aplastic anemia, further complicating the pancytopenia.